GlassScriptPhysician profile
Daniel Sirica
NPI 1609239060
$16,532.06
in general payments reported to CMS, 2019-2025
16 companies · $45.44 in 2025
The $45.44 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15K · 2021: $102 · 2022: $185 · 2023: $719 · 2024: $481 · 2025: $45.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943 · Education: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.98 |
| Education | $301.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $15,000.00 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $358.84 | 2022-2024 | Austedo Xr |
| Boston Scientific Corporation | $276.20 | 2021-2024 | |
| Abbott Laboratories | $219.60 | 2022-2024 | Infinity |
| Abbvie INC. | $143.87 | 2022-2024 | Botox, Duopa |
| Neurocrine Biosciences, INC. | $138.89 | 2023-2025 | Ingrezza, Ongentys |
| Medtronic, INC. | $110.41 | 2023 | Activa PC |
| Csl Behring | $97.75 | 2022-2024 | Hizentra |
| Ucb, INC. | $27.64 | 2025 | Fintepla |
| Grifols USA, LLC | $27.42 | 2024 | Gamunex-C |
| Revance Therapeutics, INC. | $24.28 | 2024 | Daxxify |
| Kyowa Kirin, INC. | $22.94 | 2023 | Nourianz |
| Catalyst Pharmaceuticals, INC. | $22.81 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $22.62 | 2024 | Dysport |
| Xeris Pharmaceuticals, INC. | $20.31 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $18.48 | 2023 | Gocovri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sirica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.